These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29520654)

  • 1. The 21-Gene Recurrence Score in Male Breast Cancer.
    Turashvili G; Gonzalez-Loperena M; Brogi E; Dickler M; Norton L; Morrow M; Wen HY
    Ann Surg Oncol; 2018 Jun; 25(6):1530-1535. PubMed ID: 29520654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
    Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
    Mamounas EP; Tang G; Fisher B; Paik S; Shak S; Costantino JP; Watson D; Geyer CE; Wickerham DL; Wolmark N
    J Clin Oncol; 2010 Apr; 28(10):1677-83. PubMed ID: 20065188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
    Tang G; Shak S; Paik S; Anderson SJ; Costantino JP; Geyer CE; Mamounas EP; Wickerham DL; Wolmark N
    Breast Cancer Res Treat; 2011 May; 127(1):133-42. PubMed ID: 21221771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male breast cancer: Outcome with adjuvant treatment.
    Yadav BS; Sharma SC; Singh R; Dahiya D; Ghoshal S
    J Cancer Res Ther; 2020; 16(6):1287-1293. PubMed ID: 33342786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
    Fitzal F; Filipits M; Fesl C; Rudas M; Greil R; Balic M; Moinfar F; Herz W; Dubsky P; Bartsch R; Ferree S; Schaper C; Gnant M;
    Br J Surg; 2021 Apr; 108(3):308-314. PubMed ID: 33608712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
    Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
    Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
    Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
    Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
    Kim SJ; Masuda N; Tsukamoto F; Inaji H; Akiyama F; Sonoo H; Kurebayashi J; Yoshidome K; Tsujimoto M; Takei H; Masuda S; Nakamura S; Noguchi S
    Cancer Lett; 2014 Dec; 355(2):217-23. PubMed ID: 25218592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.